These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9345394)

  • 21. Multiple sclerosis: rationale for early treatment.
    Söderström M
    Neurol Sci; 2003 Dec; 24 Suppl 5():S298-300. PubMed ID: 14652794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
    Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].
    León C; Violante A; Arriada N; Santana HR; Corona T
    Rev Neurol; 2000 Dec 1-15; 31(11):1019-22. PubMed ID: 11190865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
    Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
    Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
    Motamed MR; Najimi N; Fereshtehnejad SM
    Clin Neurol Neurosurg; 2007 May; 109(4):344-9. PubMed ID: 17300863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trials and tribulations: patients' perspectives of the Betaseron study.
    Morrison W
    Axone; 1994 Dec; 16(2):51-5. PubMed ID: 7727297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
    Koopmans RA; Paty DW
    Mult Scler; 1995; 1 Suppl 1():S22-3. PubMed ID: 9345393
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of multiple sclerosis with interferons].
    Nogales-Gaete J; Arriagada C
    Rev Med Chil; 1996 May; 124(5):597-604. PubMed ID: 9035514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
    Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
    Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon beta-1A for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1996 Jul; 38(979):63-4. PubMed ID: 8692073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.